Shots:
- The US FDA has granted FTD to BBO-8520 for the treatment of metastatic NSCLC with KRAS^G12C mutations in adults
- BBO-8520 showed significant tumor inhibition in preclinical models, post resistance to sotorasib. In addition, BBO-8520 is being assessed in a P-I (ONKORAS-101) trial in KRAS^G12C NSCLC patients either receiving KRAS^G12C inhibitors or no targeted therapy before
- BBO-8520 inhibits both “ON & OFF” states of KRASG12C, targeting resistance mechanisms like KRAS^G12C amplification & RTK activation. Developed via NCI RAS Initiative, Lawrence Livermore National Laboratory, & BBOT collaboration
Ref: BridgeBio Oncology Therapeutics | Image: BridgeBio Oncology Therapeutics
Related News:- Astellas’ Vyloy (Zolbetuximab) Secures the NMPA’s Approval as a 1L Treatment of Advanced G/GEJ Adenocarcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
